Recent Finacing
Recent Raise
Arsanis develops human monoclonal antibody therapeutics, including ASN100 for S. aureus pneumonia, plus preclinical programs targeting MDR gram-negatives, RSV and neonatal sepsis, with US and Vienna research operations.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
